AKT2 and ovarian cancer: AKT2 is linked to metabolic re−programming and invasion (30), and AKT3 correlates with cancer growth, aggressiveness and chemoresistance in ovarian cancer (31), suggesting that each isoform may contribute uniquely to the cetrorelix response.